CD40LG (CD40 ligand) variants and mutations
CD40LG (also known as CD40 ligand) is a human protein-coding gene encoding a CD40 ligand protein. It is displayed by activated CD4 T cells and engages CD40 on B cells and antigen-presenting cells to drive class switching and effective adaptive immunity. Loss-of-function variants cause X-linked hyper-IgM syndrome, with impaired immunoglobulin class switching and opportunistic infections. This analysis covers 462 CD40LG variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes hyper-IgM syndrome type 1, X-linked hyper-IgM syndrome, and hyper-IgM syndrome. Example CD40LG variants include I2I, E3K, and T4T.
Variant analysis overview
- Gene: CD40LG
- Protein: CD40 ligand
- UniProt accession: P29965
- Organism: Homo sapiens
- Variants analyzed: 462
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 274 unspecified-consequence records; 92 synonymous variants; 88 missense variants; 1 stop-gained variants; 3 frameshift variants; 1 splice-region variants; 2 in-frame deletions; 1 substitution
- Prediction scores: 397 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyper-IgM syndrome type 1, X-linked hyper-IgM syndrome, hyper-IgM syndrome, hereditary disease, systemic lupus erythematosus, common variable immunodeficiency, Sjogren syndrome, neurodegenerative disease, ulcerative colitis, sarcoidosis, inflammatory bowel disease, rheumatoid arthritis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 2 post-translational modification sites.
- Structural context: 292 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CD40LG variants
Examples include I2I, E3K, T4T, Y5*, Y5C, Y5H, Y5Y, N6K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- I2I (p.Ile2Ile), rs767236871, gnomAD X-136648254-C-T, CADD 8.81
- E3K (p.Glu3Lys), rs1350282799, ClinGen CA414751426, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65699, REVEL 0.37, MetaLR 0.38, Uncertain significance, Hyper-IgM syndrome type 1
- T4T (p.Thr4Thr), gnomAD X-136648260-A-G, CADD 0.62
- Y5* (p.Tyr5Ter), rs2148550523, ClinGen CA414751446, ClinVar RCV001384131, Ensembl rs2148550523, Pathogenic
- Y5C (p.Tyr5Cys), ExAC rs750090324, gnomAD rs750090324, REVEL 0.52, MetaLR 0.48
- Y5H (p.Tyr5His), gnomAD X-136648261-T-C, REVEL 0.40, MetaLR 0.32
- Y5Y (p.Tyr5Tyr), gnomAD X-136648263-C-T, CADD 2.62
- N6K (p.Asn6Lys), gnomAD X-136648266-C-A, REVEL 0.10, MetaLR 0.22
- T8I (p.Thr8Ile), 1000Genomes rs201109996, ExAC rs201109996, gnomAD rs201109996, REVEL 0.17, MetaLR 0.14
- S9F (p.Ser9Phe), rs1338696512, ClinGen CA414751480, ClinVar RCV001066297, TOPMed rs1338696512, REVEL 0.21, MetaLR 0.25, Uncertain significance, Hyper-IgM syndrome type 1
- P10H (p.Pro10His), gnomAD X-136648277-C-A, REVEL 0.40, MetaLR 0.51
- P10P (p.Pro10Pro), rs375387574, gnomAD X-136648278-C-G, CADD 0.48
- R11* (p.Arg11Ter), rs193922135, ClinGen CA260203, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65699, CADD 24.80, Pathogenic
- R11Q (p.Arg11Gln), rs145115086, ClinGen CA10528065, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, REVEL 0.30, MetaLR 0.42, Benign/Likely benign, not provided; Hyper-IgM syndrome type 1
- R11P (p.Arg11Pro), gnomAD X-136648280-G-C, REVEL 0.21, MetaLR 0.23
- S12S (p.Ser12Ser), gnomAD X-136648284-T-C, CADD 1.35
- A13E (p.Ala13Glu), rs368003929, ClinGen CA414751530, ClinVar RCV002575828, REVEL 0.13, MetaLR 0.17, Uncertain significance, Hyper-IgM syndrome type 1
- A13V (p.Ala13Val), rs368003929, ClinGen CA10528066, cosmic curated COSV65698, ClinVar RCV000339805, REVEL 0.12, MetaLR 0.12, Conflicting interpretations, Inborn genetic diseases; not specified; not provided
- A13A (p.Ala13Ala), rs779460863, gnomAD X-136648287-G-A, CADD 4.39
- A14T (p.Ala14Thr), cosmic curated COSV65698, Ensembl rs2076094811, REVEL 0.05, MetaLR 0.16
- A14V (p.Ala14Val), gnomAD X-136648289-C-T, REVEL 0.16, MetaLR 0.21
- T15I (p.Thr15Ile), gnomAD rs1289706273, REVEL 0.13, MetaLR 0.23
- G16E (p.Gly16Glu), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10103, MetaLR 0.43, MetaSVM -0.54, Variant assessed as somatic; moderate impact.
- L17M (p.Leu17Met), TOPMed rs1359082888, gnomAD rs1359082888, REVEL 0.13, MetaLR 0.20, Uncertain significance
- L17P (p.Leu17Pro), Ensembl rs2076094849, REVEL 0.07, MetaLR 0.15
- L17V (p.Leu17Val), rs1359082888, ClinGen CA414751583, ClinVar RCV001324502, TOPMed rs1359082888, REVEL 0.06, MetaLR 0.19, Uncertain significance, Hyper-IgM syndrome type 1
- L17L (p.Leu17Leu), gnomAD X-136648297-C-T, CADD 2.44
- P18R (p.Pro18Arg), NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, Variant assessed as somatic; moderate impact.
- P18S (p.Pro18Ser), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10103, Ensembl rs2148550549, MetaLR 0.21, MetaSVM -0.84, Variant assessed as somatic; moderate impact.
- P18T (p.Pro18Thr), gnomAD X-136648300-C-A, REVEL 0.14, MetaLR 0.21
- I19S (p.Ile19Ser), rs2522103774, ClinGen CA414751608, ClinVar RCV003209245, Uncertain significance, Inborn genetic diseases
- I19I (p.Ile19Ile), gnomAD X-136648305-C-A, CADD 3.99
- S20N (p.Ser20Asn), NCI-TCGA TCGA novel, REVEL 0.18, MetaLR 0.23, Variant assessed as somatic; moderate impact.
- S20R (p.Ser20Arg), rs2522103776, ClinGen CA414751631, ClinVar RCV003009040, REVEL 0.11, MetaLR 0.16, Uncertain significance, Hyper-IgM syndrome type 1
- S20S (p.Ser20Ser), gnomAD X-136648308-C-T, CADD 6.91
- M21I (p.Met21Ile), cosmic curated COSV10889, Ensembl rs866415103, MetaLR 0.42, MetaSVM -0.16
- M21V (p.Met21Val), gnomAD X-136648309-A-G, REVEL 0.49, MetaLR 0.39
- I23V (p.Ile23Val), gnomAD rs1359911582, REVEL 0.25, MetaLR 0.24
- F24V (p.Phe24Val), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10103, MetaLR 0.16, MetaSVM -0.93, Variant assessed as somatic; moderate impact.
- M25V (p.Met25Val), rs2076094894, ClinGen CA414751707, ClinVar RCV001343909, Ensembl rs2076094894, REVEL 0.12, MetaLR 0.17, Uncertain significance, Hyper-IgM syndrome type 1
- M25I (p.Met25Ile), gnomAD X-136648323-G-A, REVEL 0.27, MetaLR 0.26
- Y26C (p.Tyr26Cys), gnomAD rs2076094905, REVEL 0.14, MetaLR 0.14
- L27L (p.Leu27Leu), rs36063307, gnomAD X-136648329-A-G, CADD 9.32
- L28L (p.Leu28Leu), rs1273891799, gnomAD X-136648332-T-C, CADD 8.49
- T29N (p.Thr29Asn), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10103, MetaLR 0.49, MetaSVM 0.04, Variant assessed as somatic; moderate impact.
- V30A (p.Val30Ala), 1000Genomes rs186774716, ExAC rs186774716, gnomAD rs186774716, MetaLR 0.27, MetaSVM -0.77
- L32F (p.Leu32Phe), TOPMed rs1050576933, gnomAD rs1050576933, REVEL 0.35, MetaLR 0.33
- L32V (p.Leu32Val), gnomAD X-136648342-C-G, REVEL 0.11, MetaLR 0.15
- I33M (p.Ile33Met), NCI-TCGA Cosmic COSV6569, cosmic curated COSV65699, Variant assessed as somatic; moderate impact.
- I33N (p.Ile33Asn), rs1283517835, ClinGen CA414751867, ClinVar RCV001027559, ClinVar RCV006465072, AlphaMissense 0.80, MetaLR 0.44, Uncertain significance, Common variable immunodeficiency; Hyper-IgM syndrome type 1
- I33S (p.Ile33Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- I33T (p.Ile33Thr), gnomAD rs1283517835, MetaLR 0.18, MetaSVM -0.84, Uncertain significance
- I33V (p.Ile33Val), TOPMed rs1306957056, gnomAD rs1306957056, REVEL 0.17, MetaLR 0.20
- I33I (p.Ile33Ile), rs2057682025, gnomAD X-136648347-C-T, CADD 10.20
- T34S (p.Thr34Ser), gnomAD X-136648348-A-T, REVEL 0.18, MetaLR 0.15
- Q35H (p.Gln35His), NCI-TCGA TCGA novel, MetaLR 0.40, MetaSVM -0.36, Variant assessed as somatic; moderate impact.
- M36I (p.Met36Ile), rs2076095000, ClinGen CA414751909, cosmic curated COSV65698, ClinVar RCV001059437, AlphaMissense 0.50, MetaLR 0.15, Uncertain significance, Hyper-IgM syndrome type 1
- M36K (p.Met36Lys), rs104894774, ClinGen CA16621207, ClinVar RCV000480912, ClinVar RCV001368065, AlphaMissense 0.93, MetaLR 0.22, Conflicting interpretations, not provided; Hyper-IgM syndrome type 1
- M36R (p.Met36Arg), rs104894774, ClinGen CA255749, ClinVar RCV000011912, UniProt VAR 007513, AlphaMissense 0.93, MetaLR 0.22, Pathogenic/Likely pathogenic, Hyper-IgM syndrome type 1
- M36T (p.Met36Thr), rs104894774, ClinGen CA414751908, ClinVar RCV002025811, Ensembl rs104894774, AlphaMissense 0.93, MetaLR 0.22, Uncertain significance, Hyper-IgM syndrome type 1
- M36V (p.Met36Val), NCI-TCGA TCGA novel, MetaLR 0.19, MetaSVM -0.91, Variant assessed as somatic; moderate impact., in HIGM1
- I37S (p.Ile37Ser), NCI-TCGA TCGA novel, MetaLR 0.49, MetaSVM 0.03, Variant assessed as somatic; moderate impact.
- I37I (p.Ile37Ile), gnomAD X-136648359-T-C, CADD 11.20
- G38R (p.Gly38Arg), UniProt VAR 017925, MetaLR 0.42, MetaSVM -0.15, Pathogenic, in HIGM1
- G38W (p.Gly38Trp), gnomAD X-136648360-G-T, REVEL 0.61, MetaLR 0.45
- G38G (p.Gly38Gly), rs767319189, gnomAD X-136648362-G-A, CADD 8.28
- S39* (p.Ser39Ter), gnomAD X-136648364-C-A, CADD 37.00
- L41F (p.Leu41Phe), gnomAD rs1216770048
- L41P (p.Leu41Pro), rs2148550578, ClinGen CA414752158, ClinVar RCV001372922, Ensembl rs2148550578, AlphaMissense 0.82, MetaLR 0.39, Uncertain significance, Hyper-IgM syndrome type 1
- L41V (p.Leu41Val), gnomAD rs1216770048, REVEL 0.19, MetaLR 0.31
- F42F (p.Phe42Phe), gnomAD X-136648374-T-C, CADD 12.10
- A43V (p.Ala43Val), gnomAD X-136648376-C-T, REVEL 0.39, MetaLR 0.28
- V44V (p.Val44Val), gnomAD X-136648380-G-A, CADD 5.96
- Y45N (p.Tyr45Asn), NCI-TCGA TCGA novel, MetaLR 0.44, MetaSVM -0.11, Variant assessed as somatic; moderate impact.
- L46F (p.Leu46Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L46R (p.Leu46Arg), rs2522103903, ClinGen CA414752193, ClinVar RCV003056268, Uncertain significance, Hyper-IgM syndrome type 1
- L46V (p.Leu46Val), gnomAD X-136648384-C-G, REVEL 0.43, MetaLR 0.45
- H47L (p.His47Leu), TOPMed rs1008946391, gnomAD rs1008946391, REVEL 0.50, MetaLR 0.45
- H47H (p.His47His), gnomAD X-136648389-T-C, CADD 8.84
- R48K (p.Arg48Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R48G (p.Arg48Gly), gnomAD X-136648390-A-G, REVEL 0.47, MetaLR 0.36
- R49R (p.Arg49Arg), gnomAD X-136648395-G-A, CADD 9.96
- L50V (p.Leu50Val), 1000Genomes rs1126535, ESP rs1126535, ExAC rs1126535, TOPMed rs1126535, MetaLR 0.40, MetaSVM -0.22, Benign
- L50L (p.Leu50Leu), rs1126535, gnomAD X-136648396-T-C, CADD 6.53
- D51G (p.Asp51Gly), ExAC rs771141566, gnomAD rs771141566, REVEL 0.51, MetaLR 0.41
- D51E (p.Asp51Glu), gnomAD X-136648401-C-A, REVEL 0.38, MetaLR 0.36
- K52T (p.Lys52Thr), gnomAD X-136648403-A-C, REVEL 0.40, MetaLR 0.43
- I53T (p.Ile53Thr), ExAC rs778219718, TOPMed rs778219718, gnomAD rs778219718, REVEL 0.29, MetaLR 0.21, Uncertain significance, Hyper-IgM syndrome type 1
- I53V (p.Ile53Val), gnomAD X-136650266-A-G, REVEL 0.04, MetaLR 0.14
- I53R (p.Ile53Arg), gnomAD X-136650267-T-G, REVEL 0.41, MetaLR 0.28
- I53M (p.Ile53Met), gnomAD X-136650268-A-G, REVEL 0.10, MetaLR 0.13
- E54Q (p.Glu54Gln), NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, MetaLR 0.18, MetaSVM -0.78, Variant assessed as somatic; moderate impact.
- E54E (p.Glu54Glu), gnomAD X-136650271-A-G, CADD 11.30
- D55R (p.Asp55Arg), rs2522106375, ClinGen CA2580101571, ClinVar RCV002285110, Pathogenic
- D55D (p.Asp55Asp), rs372639733, gnomAD X-136650274-T-C, CADD 10.10
- E56* (p.Glu56Ter), rs2148551084, ClinGen CA414752798, ClinVar RCV004819198, Ensembl rs2148551084, Pathogenic
- E56D (p.Glu56Asp), TOPMed rs2076100334, gnomAD rs2076100334, REVEL 0.25, MetaLR 0.36
- E56K (p.Glu56Lys), gnomAD X-136650275-G-A, REVEL 0.35, MetaLR 0.42
- E56G (p.Glu56Gly), gnomAD X-136650276-A-G, REVEL 0.44, MetaLR 0.42
- E56E (p.Glu56Glu), gnomAD X-136650277-A-G, CADD 11.80
- R57K (p.Arg57Lys), NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, Variant assessed as somatic; moderate impact.
- R57G (p.Arg57Gly), gnomAD X-136650275-GA-G, CADD 27.80
- R57M (p.Arg57Met), gnomAD X-136650279-G-T, REVEL 0.10, MetaLR 0.16
- R57R (p.Arg57Arg), gnomAD X-136650280-G-A, CADD 12.50
- N58D (p.Asn58Asp), gnomAD X-136650281-A-G, REVEL 0.18, MetaLR 0.19
- L59I (p.Leu59Ile), cosmic curated COSV10103, 1000Genomes rs749829408, ExAC rs749829408, gnomAD rs749829408, REVEL 0.27, MetaLR 0.37, Uncertain significance, Hyper-IgM syndrome type 1
- L59L (p.Leu59Leu), gnomAD X-136650286-T-C, CADD 11.60
- H60Y (p.His60Tyr), gnomAD rs2076100370, REVEL 0.08, MetaLR 0.18
- H60H (p.His60His), gnomAD X-136650289-T-C, CADD 6.87
- H60Q (p.His60Gln), gnomAD X-136650289-T-G, REVEL 0.07, MetaLR 0.15
- E61E (p.Glu61Glu), gnomAD X-136650292-A-G, CADD 8.28
- V64A (p.Val64Ala), rs771501540, ClinGen CA10528089, ClinVar RCV003838759, 1000Genomes rs771501540, REVEL 0.38, MetaLR 0.28, Benign, Hyper-IgM syndrome type 1
- V64V (p.Val64Val), rs2076100412, gnomAD X-136650301-A-G, CADD 10.20
- F65L (p.Phe65Leu), gnomAD X-136650304-C-A, REVEL 0.49, MetaLR 0.43
- M66K (p.Met66Lys), gnomAD X-136650306-T-A, REVEL 0.36, MetaLR 0.22
- K67R (p.Lys67Arg), gnomAD X-136650309-A-G, REVEL 0.18, MetaLR 0.17
- T68M (p.Thr68Met), rs2148551094, ClinGen CA414753119, ClinVar RCV001890078, Ensembl rs2148551094, REVEL 0.12, MetaLR 0.17, Uncertain significance, Hyper-IgM syndrome type 1
- T68K (p.Thr68Lys), gnomAD X-136650312-C-A, REVEL 0.10, MetaLR 0.12
- T68T (p.Thr68Thr), rs775209130, gnomAD X-136650313-G-A, CADD 7.40
- Q70* (p.Gln70Ter), rs2148551102, ClinGen CA414753158, ClinVar RCV003066381, AlphaMissense 0.16, MetaLR 0.21, Pathogenic
- Q70E (p.Gln70Glu), rs2148551102, ClinGen CA414753154, ClinVar RCV001907736, Ensembl rs2148551102, AlphaMissense 0.16, MetaLR 0.21, Uncertain significance, Hyper-IgM syndrome type 1
- Q70K (p.Gln70Lys), gnomAD X-136650317-C-A, REVEL 0.05, MetaLR 0.18
- Q70P (p.Gln70Pro), gnomAD X-136650318-A-C, REVEL 0.44, MetaLR 0.37
- Q70Q (p.Gln70Gln), gnomAD X-136650319-G-A, CADD 9.12
- C72* (p.Cys72Ter), rs1556136635, ClinGen CA414753207, ClinVar RCV000523806, Ensembl rs1556136635, Pathogenic
- C72C (p.Cys72Cys), gnomAD X-136650325-C-T, CADD 10.40
- T74K (p.Thr74Lys), gnomAD X-136650330-C-A, REVEL 0.10, MetaLR 0.12
- T74T (p.Thr74Thr), gnomAD X-136650331-A-G, CADD 11.20
- G75E (p.Gly75Glu), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, Variant assessed as somatic; moderate impact.
- G75R (p.Gly75Arg), ExAC rs771120303, gnomAD rs771120303, REVEL 0.43, MetaLR 0.27
- G75V (p.Gly75Val), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10103, NCI-TCGA Cosmic COSV6569, MetaLR 0.23, MetaSVM -0.79, Variant assessed as somatic; moderate impact.
- G75G (p.Gly75Gly), gnomAD X-136650334-A-G, CADD 9.92
- E76K (p.Glu76Lys), gnomAD rs1329862058, REVEL 0.24, MetaLR 0.29
- E76Q (p.Glu76Gln), gnomAD X-136650335-G-C, REVEL 0.14, MetaLR 0.30
- R77D (p.Arg77Asp), rs2522106494, ClinGen CA2580101574, ClinVar RCV002468418, Pathogenic
- R77R (p.Arg77Arg), rs1376637717, gnomAD X-136650340-A-G, CADD 4.55
- S78P (p.Ser78Pro), rs200672738, ClinGen CA10528093, ClinVar RCV002068672, ClinVar RCV004962955, REVEL 0.15, MetaLR 0.20, Conflicting interpretations, Inborn genetic diseases; Hyper-IgM syndrome type 1
- S78T (p.Ser78Thr), 1000Genomes rs200672738, ExAC rs200672738, TOPMed rs200672738, gnomAD rs200672738, REVEL 0.13, MetaLR 0.20, Benign
- S78S (p.Ser78Ser), gnomAD X-136650343-C-T, CADD 4.03
- L79L (p.Leu79Leu), rs769933625, gnomAD X-136650346-A-G, CADD 8.06
- S80P (p.Ser80Pro), Ensembl rs2148551112, MetaLR 0.20, MetaSVM -0.79, Uncertain significance, Hyper-IgM syndrome type 1
- S80S (p.Ser80Ser), gnomAD X-136650349-C-A, CADD 8.17
- L81F (p.Leu81Phe), ESP rs376406003, TOPMed rs376406003, gnomAD rs376406003, REVEL 0.32, MetaLR 0.38
- L81Y (p.Leu81Tyr), gnomAD X-136650349-CT-C, CADD 22.80
- L81I (p.Leu81Ile), gnomAD X-136650350-T-A, REVEL 0.19, MetaLR 0.32
- L82R (p.Leu82Arg), 1000Genomes rs768391352, ExAC rs768391352, gnomAD rs768391352, REVEL 0.64, MetaLR 0.44
- N83K (p.Asn83Lys), ExAC rs761769948, gnomAD rs761769948, REVEL 0.42, MetaLR 0.42
- N83N (p.Asn83Asn), gnomAD X-136650358-C-T, CADD 8.74
- C84C (p.Cys84Cys), rs1430792179, gnomAD X-136650361-T-C, CADD 10.90
- E85G (p.Glu85Gly), gnomAD X-136650363-A-G, REVEL 0.31, MetaLR 0.27
- E86K (p.Glu86Lys), rs1556136676, ClinGen CA414753468, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, AlphaMissense 0.08, MetaLR 0.18, Uncertain significance, not specified
- E86V (p.Glu86Val), gnomAD X-136650366-A-T, REVEL 0.36, MetaLR 0.28
- I87V (p.Ile87Val), ESP rs369975696, ExAC rs369975696, TOPMed rs369975696, gnomAD rs369975696, REVEL 0.07, MetaLR 0.19
- I87F (p.Ile87Phe), gnomAD X-136650368-A-T, REVEL 0.31, MetaLR 0.29
- K88E (p.Lys88Glu), NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, MetaLR 0.15, MetaSVM -0.99, Variant assessed as somatic; moderate impact.
- S89R (p.Ser89Arg), TOPMed rs2076100619, MetaLR 0.15, MetaSVM -1.03
- Q90* (p.Gln90Ter), rs2522106594, ClinGen CA414753576, ClinVar RCV002823885, ClinVar RCV003222445, Pathogenic
- Q90H (p.Gln90His), rs2076100638, ClinGen CA414753582, ClinVar RCV003512422, gnomAD rs2076100638, REVEL 0.06, MetaLR 0.17, Uncertain significance, Hyper-IgM syndrome type 1
- Q90Q (p.Gln90Gln), gnomAD X-136650379-G-A, CADD 6.30
- F91S (p.Phe91Ser), gnomAD X-136650381-T-C, REVEL 0.62, MetaLR 0.37
- F94V (p.Phe94Val), gnomAD X-136650389-T-G, REVEL 0.05, MetaLR 0.15
- K96=, NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; low impact.
- D97G (p.Asp97Gly), rs1004051141, ClinGen CA336266740, ClinVar RCV002039357, TOPMed rs1004051141, REVEL 0.12, MetaLR 0.17, Uncertain significance, Hyper-IgM syndrome type 1
- D97D (p.Asp97Asp), gnomAD X-136654375-T-C, CADD 0.09
- I98M (p.Ile98Met), cosmic curated COSV65699, TOPMed rs2076113123, REVEL 0.26, MetaLR 0.25
- I98V (p.Ile98Val), gnomAD X-136654376-A-G, REVEL 0.21, MetaLR 0.25
- I98T (p.Ile98Thr), gnomAD X-136654377-T-C, REVEL 0.17, MetaLR 0.21
- L100* (p.Leu100Ter), rs2522111616, ClinGen CA414754560, ClinVar RCV002899648, Pathogenic
- L100F (p.Leu100Phe), gnomAD X-136654384-A-C, REVEL 0.12, MetaLR 0.26
- N101S (p.Asn101Ser), gnomAD X-136654386-A-G, REVEL 0.11, MetaLR 0.21
- K102E (p.Lys102Glu), gnomAD X-136654388-A-G, REVEL 0.09, MetaLR 0.18
- K102R (p.Lys102Arg), gnomAD X-136654389-A-G, REVEL 0.17, MetaLR 0.23
- E103* (p.Glu103Ter), NCI-TCGA TCGA novel, Ensembl rs2076113150, Variant assessed as somatic; high impact.
- E104K (p.Glu104Lys), rs752210787, NCI-TCGA Cosmic COSV6569, cosmic curated COSV65698, ExAC rs752210787, REVEL 0.07, MetaLR 0.15, Variant assessed as somatic; moderate impact.
- T105K (p.Thr105Lys), rs376582437, ClinGen CA414754678, ClinVar RCV003512685, ESP rs376582437, AlphaMissense 0.08, MetaLR 0.15, Uncertain significance, Hyper-IgM syndrome type 1
- T105M (p.Thr105Met), rs376582437, ClinGen CA10528112, ClinVar RCV001514818, ESP rs376582437, REVEL 0.10, AlphaMissense 0.08, Benign, Hyper-IgM syndrome type 1
- T105A (p.Thr105Ala), gnomAD X-136654397-A-G, REVEL 0.05, MetaLR 0.13
- T105P (p.Thr105Pro), gnomAD X-136654397-A-C, REVEL 0.07, MetaLR 0.12
- T105T (p.Thr105Thr), rs778398894, gnomAD X-136654399-G-A, CADD 6.42
- K107E (p.Lys107Glu), cosmic curated COSV65698, TOPMed rs1257414276, gnomAD rs1257414276, REVEL 0.15, MetaLR 0.21
Public CD40LG analysis runs
- CD40LG analysis run — CD40LG (462 variants) — completed 2026-08-19